351 related articles for article (PubMed ID: 35176098)
1. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
Mizuno H; Sekine A; Suwabe T; Ikuma D; Yamanouchi M; Hasegawa E; Sawa N; Ubara Y; Hoshino J
PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098
[TBL] [Abstract][Full Text] [Related]
2. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
Oguro M; Kogure Y; Hoshino J; Ubara Y; Mizuno H; Sekine A; Kawada M; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takaichi K
J Nephrol; 2018 Dec; 31(6):961-966. PubMed ID: 30357715
[TBL] [Abstract][Full Text] [Related]
3. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945
[TBL] [Abstract][Full Text] [Related]
4. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT
Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153
[TBL] [Abstract][Full Text] [Related]
6. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
7. [Tolvaptan, a vasopressin V
Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
[TBL] [Abstract][Full Text] [Related]
8. Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD).
Makabe S; Mochizuki T; Mitobe M; Aoyama Y; Kataoka H; Tsuchiya K; Nitta K
Clin Exp Nephrol; 2018 Oct; 22(5):1079-1087. PubMed ID: 29508162
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Casteleijn NF; Blais JD; Chapman AB; Czerwiec FS; Devuyst O; Higashihara E; Leliveld AM; Ouyang J; Perrone RD; Torres VE; Gansevoort RT;
Am J Kidney Dis; 2017 Feb; 69(2):210-219. PubMed ID: 27856088
[TBL] [Abstract][Full Text] [Related]
11. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
Xie X; Cai Q; Guo XY; Bai DH; Sheng HZ; Wang BK; Yan K; Lu AM; Wang XR
Comb Chem High Throughput Screen; 2020; 23(1):6-16. PubMed ID: 31793415
[TBL] [Abstract][Full Text] [Related]
13. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Pharmacokinetics and Implications for Practice.
Hines CB; Hooper GL; Collins-Yoder A
Nephrol Nurs J; 2020; 47(2):145-150. PubMed ID: 32343088
[TBL] [Abstract][Full Text] [Related]
15. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
[TBL] [Abstract][Full Text] [Related]
16. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
Muto S; Okada T; Shibasaki Y; Ibuki T; Horie S
Clin Exp Nephrol; 2021 Sep; 25(9):1003-1010. PubMed ID: 34089122
[TBL] [Abstract][Full Text] [Related]
17. A
Shoaf SE; Ouyang J; Sergeyeva O; Estilo A; Li H; Leung D
Clin J Am Soc Nephrol; 2020 May; 15(5):643-650. PubMed ID: 32241780
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
19. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M
Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201
[TBL] [Abstract][Full Text] [Related]
20. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
Muto S; Kawano H; Higashihara E; Narita I; Ubara Y; Matsuzaki T; Ouyang J; Torres VE; Horie S
Clin Exp Nephrol; 2015 Oct; 19(5):867-77. PubMed ID: 25663351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
